Jiangsu Hengrui Pharmaceuticals News

Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensiv

Zhitong FinanceApr 25 17:37

Hengrui Pharmaceutical (600276): The share of innovative drug revenue continues to increase, and the internationalization process is progressing steadily

東吳證券Apr 24 16:01

Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in perfo

Zhitong FinanceApr 24 15:14

Hengrui Pharmaceutical (600276): Stable performance and continuous growth in revenue from innovative drugs

海通證券Apr 23 20:21

Hengrui?? Medicine (600276): Innovative drugs drive performance growth and lead the development of the innovative pharmaceutical industry

光大證券Apr 23 12:06

Hengrui Pharmaceutical (600276) Review Report: Revenue from innovative drugs is growing steadily, R&D and internationalization are accelerating

國海證券Apr 23 00:00

China Galaxy released a research report on April 22 stating that Hengrui Pharmaceutical (600276.SH) was given a recommended rating. The main reasons for the rating include: 1) continuous implementation of innovative achievements to drive steady revenue gr

Zhitong FinanceApr 22 07:51

Southwest Securities released a research report on April 21 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) steady improvement in performance and profitability; 2) continuous approval

Zhitong FinanceApr 21 09:40

Hengrui Pharmaceutical (600276) Review: Innovative drugs break through the 10 billion mark and continue to innovate and upgrade

申萬宏源研究Apr 21 00:00

Hengrui Pharmaceutical (600276): Performance is in line with expectations, focus on innovative drug sales and pipeline progress

中金公司Apr 21 00:00

Hengrui Pharmaceutical (600276): Steady growth in performance, accelerated implementation of innovative achievements

國泰君安Apr 19 16:11

Hengrui Pharmaceutical (600276): Strengthening early research and technology platform construction, high-quality innovation achievements continue to be approved

民生證券Apr 19 07:16

Hengrui Pharmaceutical (600276) 2023 Annual Report and Quarterly Report Review: Innovative Drugs Drive Revenue Growth and Accelerate the Internationalization Process

西部證券Apr 19 00:00

Hengrui Pharmaceutical (600276): Results for the fiscal year 23 and the first quarter of '24 are in line with expectations: overall performance rebounded steadily, innovative drugs grew strongly

方正證券Apr 19 00:00

Bank of China Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) The company released the 2023 report and the 2024 quarterly report, and

Zhitong FinanceApr 18 16:43

Guojin Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) the gradual implementation of the results of innovation and transformation; 2)

Zhitong FinanceApr 18 09:55

Hengrui Pharmaceutical (600276): Innovation drives strong overseas layout to reach many milestones

國金證券Apr 18 08:36

Hengrui Pharmaceutical (600276): Rapid revenue growth of innovative drugs continues to strengthen innovation at the source

西南證券Apr 18 00:00

Hengrui Pharmaceutical (600276): Innovative drugs continue to contribute to increased performance, and many new varieties have entered the implementation stage

國投證券Apr 18 00:00

Hengrui Pharmaceutical (600276): The pain of transformation has passed, innovation has come to an end

長江證券Mar 19 21:01